Search for content, post, videos

Simeprevir receives positive CHMP opinion

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients.

“The recommendation is one additional step in the global strategy that our partner Janssen has for simeprevir, to offer a new and efficacious treatment option to the many hepatitis C patient groups suffering from this devastating disease,” said Maris Hartmanis CEO, Medivir.

Simeprevir is developed as a treatment of chronic hepatitis C through a collaboration between Medivir and Janssen. The pharmaceutical has previously been approved in Japan, Canada and the United States.